TNF and infection: ,38,40,55–58,68,72,76,78,79,91,93 The most commonly administered biologic was vedolizumab (n = 339) with a pooled all-cause infection event rate of 15.8% (95% CI, 7.4%-24.1%, I2 = 83.4%),37,55–57,78,91 followed by anti-TNFα therapies which were associated with an all-cause infection event rate of 7.7% (95% CI, 2.5%-12.9%, I2 = 3.3%).38